Exopharm

Melbourne, Australia
Find alternatives to Exopharm for Exosome →
Program data pending ClinicalTrials.gov matching · Last scored 2026-10-29
56.5
Signal Score
○ FDA Inspections ○ Clinical Trials ○ SEC Filings ○ Press ○ EMA GMP ○ MHRA GMP

Quick Facts: Exopharm

Signal Score
56.5/100 (as of 2026-10-29)
Quality Compliance
Assessment pending
Headquarters
Melbourne, Australia
Modalities
Exosome
Active Programs
No ClinicalTrials.gov matches confirmed
Data Sources
FDA Data Dashboard, ClinicalTrials.gov, SEC EDGAR, press monitoring
Scored By
CDMO Signal — independent CDMO intelligence platform

About Exopharm

Pure-play CDMO.

Signal Score & Pillar Breakdown

Quality Compliance —
No FDA inspection records found. This CDMO may operate under a different legal name or may not have US FDA-inspected facilities.
FDA InspectionsNo US records on file
No FDA inspection records found for this manufacturer
Quality score requires FDA inspection data
Operations —
No ClinicalTrials.gov facility matches confirmed for this manufacturer.
Programs — no verified data
Sponsors— no verified data
ModalitiesExosome
No clinical trial matches found for this manufacturer
Operational score requires ClinicalTrials.gov data
Scored from ClinicalTrials.gov and FDA records; SEC EDGAR and press items are shown as company signals, not scored. No unverified estimates shown.
Financial Stability 60.0
Private company
Financial assessment: 60.0/100
Source: company profile (public/private status, parent company)
Profile-based financial assessment
SEC FilingsPrivate company
Private company
Financial assessment: 60.0/100
Capacity 53.0
1 manufacturing site: Melbourne, AU
Modalities: Exosome
Capacity assessment: 53.0/100
Sites: Melbourne, AU
Source: company profiles (manufacturing sites, modality breadth)
1 manufacturing site
1 manufacturing site: Melbourne, AU
Modalities: Exosome
Capacity assessment: 53.0/100

Hiring Activity Beta

Built from public job postings when a company's own roles can be read. Job postings are signals, not statements by the company; each one below links to the original. How we collect this
No hiring data yet. We haven't found a public jobs feed for this company.
Source: public careers pages · Checked Nov 20, 2026

Frequently Asked Questions About Exopharm

What is Exopharm's CDMO Signal Score?
Exopharm has a Signal Score of 56/100, based on quality, operations, financial stability, and capacity data.
Evaluating Exopharm for a manufacturing program?
Use the free AI matchmaker to compare Exopharm against other CDMOs by FDA, EMA, and clinical-trial data — no login required.
Find & compare CDMOs →
Represent this organization? Contact us to verify or update this profile.
See all CDMOs in:
Exosome CDMOs →

Similar CDMOs

Esco Aster
Singapore, Singapore
Signal Score: 63.0
Cell Therapy, Exosome
Codiak BioSciences (Sarepta)
Cambridge, MA
Signal Score: 60.3
Exosome
ExoXpert (EXO Biologics)
Liège, Belgium
Signal Score: 56.5
Exosome
Evox Therapeutics
Oxford, United Kingdom
Signal Score: 56.5
Exosome
Clara Biotech
Indianapolis, IN
Signal Score: 56.5
Exosome

Compare Exopharm with another CDMO

Side-by-side scoring, FDA inspection history, EMA/MHRA GMP coverage, and clinical-program footprint.
Compare side-by-side
See two CDMOs' scoring, inspection history, and clinical footprint next to each other.
Open comparison →
Run a sourcing search
Describe your program's requirements — Signal matches CDMOs against FDA, EMA/MHRA, ClinicalTrials.gov and capacity signals.
Search for a CDMO →
Get updates on Exopharm
Get an email when a CDMO on this list has a new FDA inspection, GMP certificate, or scoring change.